EMA Medicine safety communications
Cibinqo / Jyseleca / Olumiant / Rinvoq / Xeljanz: referral - article 20 procedure
Published by European Medicines Agency: · Ref. EMEA/H-A20/1517/C/004214/0048; EMEA/H-A20/1517/C/005452/0003
Summary
Referral - Article 20 procedure
- Related referral: Janus kinase inhibitors (JAKi)
Medicine
Cibinqo / Jyseleca / Olumiant / Rinvoq / Xeljanz
- Category
- Medicine safety communications
- Product type
- Human medicine
- Active substance(s): abrocitinib;filgotinib;baricitinib;upadacitinib;tofacitinib
- Therapeutic area: Arthritis, Rheumatoid;Dermatitis, Atopic
- ATC code: D11AH08;L04AA45;L04AA37;L04AA44;L04AA29
Measures and alternatives
- Regulatory outcome: Variation
Source: EMA — medicine safety communications — European Medicines Agency
Source: European Medicines Agency (EMA). Reproduced with acknowledgement of the source, in line with the EMA legal notice. EU Safety Radar is an independent information service; the text above presents the official data in the original language — the notice published by the authority is authoritative.
Open the original notice (www.ema.europa.eu) ↗